Abstract
From September 1976 to June 1982, 201 consecutive patients with stage I (A and B)-IIA Hodgkin's disease were stratified in two groups according to prognostic factors. The F group included 116 patients with favourable presentation: they were staged with laparotomy and treated with subtotal or total nodal radiotherapy alone. The U group included 85 cases with unfavourable presentation who were staged by laparoscopy and treated with 3MOPP (mechlorethamine, vincristine, procarbazine, prednisone)-radiotherapy-3MOPP. At 10 years the F group showed a freedom from progression (FFP) of 71%, with significant difference between stage I and II (85% vs. 59%; P=0.003) and an overall survival of 84%. The results of the U group were: FFP 83%, overall survival 74%, and the findings were not influenced by stage. FFP in patients with bulky vs. not bulky lymphoma was 70% vs. 87% (P=0.04). No secondary acute non-lymphocytic leukaemia developed among patients treated with radiotherapy and in continuous complete remission, while acute leukaemia occurred in the F group patients who received salvage chemotherapy (4 of 31 cases) and in the U group (3 of 85 cases). Present results confirm the usefulness of radiotherapy alone in favourable pathological stage IA. All other disease stages will require a different strategy that should consist of radiotherapy combined with short-term effective regimens, such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or VBM (vinblastine, bleomycin and methotrexate) to reduce the incidence of MOPP-associated gonadal dysfunction and leukaemogenesis.
| Original language | English |
|---|---|
| Pages (from-to) | 24-29 |
| Number of pages | 6 |
| Journal | European Journal of Cancer |
| Volume | 29 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1993 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Early stage Hodgkin's disease : Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP. / Bonfante, Valeria; Santoro, Armando; Viviani, Simonetta; Zucali, Roberto; Devizzi, Liliana; Zanini, Marcello; Tess, John David Tesoro; Valagussa, Pinuccia; Banfi, Alberto; Bonadonna, Gianni.
In: European Journal of Cancer, Vol. 29, No. 1, 1993, p. 24-29.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Early stage Hodgkin's disease
T2 - Ten-year results of a non-randomised study with radiotherapy alone or combined with MOPP
AU - Bonfante, Valeria
AU - Santoro, Armando
AU - Viviani, Simonetta
AU - Zucali, Roberto
AU - Devizzi, Liliana
AU - Zanini, Marcello
AU - Tess, John David Tesoro
AU - Valagussa, Pinuccia
AU - Banfi, Alberto
AU - Bonadonna, Gianni
PY - 1993
Y1 - 1993
N2 - From September 1976 to June 1982, 201 consecutive patients with stage I (A and B)-IIA Hodgkin's disease were stratified in two groups according to prognostic factors. The F group included 116 patients with favourable presentation: they were staged with laparotomy and treated with subtotal or total nodal radiotherapy alone. The U group included 85 cases with unfavourable presentation who were staged by laparoscopy and treated with 3MOPP (mechlorethamine, vincristine, procarbazine, prednisone)-radiotherapy-3MOPP. At 10 years the F group showed a freedom from progression (FFP) of 71%, with significant difference between stage I and II (85% vs. 59%; P=0.003) and an overall survival of 84%. The results of the U group were: FFP 83%, overall survival 74%, and the findings were not influenced by stage. FFP in patients with bulky vs. not bulky lymphoma was 70% vs. 87% (P=0.04). No secondary acute non-lymphocytic leukaemia developed among patients treated with radiotherapy and in continuous complete remission, while acute leukaemia occurred in the F group patients who received salvage chemotherapy (4 of 31 cases) and in the U group (3 of 85 cases). Present results confirm the usefulness of radiotherapy alone in favourable pathological stage IA. All other disease stages will require a different strategy that should consist of radiotherapy combined with short-term effective regimens, such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or VBM (vinblastine, bleomycin and methotrexate) to reduce the incidence of MOPP-associated gonadal dysfunction and leukaemogenesis.
AB - From September 1976 to June 1982, 201 consecutive patients with stage I (A and B)-IIA Hodgkin's disease were stratified in two groups according to prognostic factors. The F group included 116 patients with favourable presentation: they were staged with laparotomy and treated with subtotal or total nodal radiotherapy alone. The U group included 85 cases with unfavourable presentation who were staged by laparoscopy and treated with 3MOPP (mechlorethamine, vincristine, procarbazine, prednisone)-radiotherapy-3MOPP. At 10 years the F group showed a freedom from progression (FFP) of 71%, with significant difference between stage I and II (85% vs. 59%; P=0.003) and an overall survival of 84%. The results of the U group were: FFP 83%, overall survival 74%, and the findings were not influenced by stage. FFP in patients with bulky vs. not bulky lymphoma was 70% vs. 87% (P=0.04). No secondary acute non-lymphocytic leukaemia developed among patients treated with radiotherapy and in continuous complete remission, while acute leukaemia occurred in the F group patients who received salvage chemotherapy (4 of 31 cases) and in the U group (3 of 85 cases). Present results confirm the usefulness of radiotherapy alone in favourable pathological stage IA. All other disease stages will require a different strategy that should consist of radiotherapy combined with short-term effective regimens, such as ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or VBM (vinblastine, bleomycin and methotrexate) to reduce the incidence of MOPP-associated gonadal dysfunction and leukaemogenesis.
UR - http://www.scopus.com/inward/record.url?scp=0027420187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027420187&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(93)90570-6
DO - 10.1016/0959-8049(93)90570-6
M3 - Article
C2 - 1445741
AN - SCOPUS:0027420187
VL - 29
SP - 24
EP - 29
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 1
ER -